Press Releases

Press Releases

Date Title Files

May 06, 2021

Dynavax Announces First Quarter 2021 Financial Results

May 04, 2021

Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 27, 2021

HEPLISAV-B Post-Marketing Observational Study Results Presented at 2021 Annual Conference on Vaccinology Research (ACVR)

Apr 22, 2021

Dynavax to Report First Quarter 2021 Financial Results and Host Conference Call on May 6, 2021

Apr 21, 2021

Valneva Initiates Pivotal Phase 3 Clinical Trial for its Inactivated, COVID-19 Vaccine Candidate using Dynavax's CpG 1018™ Adjuvant

Apr 19, 2021

Two HEPLISAV-B Abstracts Selected for Oral Presentation at the 2021 Annual Conference on Vaccinology Research (ACVR)

Apr 06, 2021

Positive Phase 1/2 Results for Valneva's Inactivated COVID-19 Vaccine Candidate Using Dynavax's CpG 1018™ Adjuvant

Apr 02, 2021

Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 24, 2021

Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine Candidate

Mar 01, 2021

Dynavax to Present at the H.C. Wainwright Virtual 2021 Global Life Sciences Conference